July 21, 2023Open Access

Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

These findings suggest that concomitant use of PPIs with palbociclib may hinder the complete therapeutic benefits of palbociclib in patients with breast cancer.

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Lee et al. (Fri,) studied this question.

synapsesocial.com/papers/69dce903a6f240e91f1334de https://doi.org/https://doi.org/10.1001/jamanetworkopen.2023.24852

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.2022 · 6 citations
2Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future2020 · 467 citations
3Health for all in the Republic of Korea: one country's experience with implementing universal health care1995 · 59 citations
4Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib2017 · 204 citations
5Landmark analysis: A primer2019 · 215 citations